Weekly Investment Analysts’ Ratings Updates for Insulet (PODD)

A number of firms have modified their ratings and price targets on shares of Insulet (NASDAQ: PODD) recently:

• 2/19/2026 – Insulet had its price target lowered by Truist Financial Corporation from $390.00 to $360.00. They now have a “buy” rating on the stock.
• 2/19/2026 – Insulet was given a new $340.00 price target by Evercore Inc.
• 2/19/2026 – Insulet had its price target lowered by The Goldman Sachs Group, Inc. from $363.00 to $326.00. They now have a “buy” rating on the stock.
• 2/19/2026 – Insulet had its price target lowered by Oppenheimer Holdings, Inc. from $365.00 to $300.00. They now have an “outperform” rating on the stock.
• 2/19/2026 – Insulet had its price target lowered by Sanford C. Bernstein from $380.00 to $330.00. They now have an “outperform” rating on the stock.
• 2/19/2026 – Insulet had its “underweight” rating reaffirmed by Barclays PLC. They now have a $286.00 price target on the stock.
• 2/19/2026 – Insulet had its price target lowered by Raymond James Financial, Inc. from $385.00 to $355.00. They now have an “outperform” rating on the stock.
• 2/19/2026 – Insulet had its price target lowered by Citigroup Inc. from $380.00 to $345.00. They now have a “buy” rating on the stock.
• 2/19/2026 – Insulet had its price target lowered by JPMorgan Chase & Co. from $415.00 to $340.00. They now have an “overweight” rating on the stock.
• 2/19/2026 – Insulet had its price target lowered by Leerink Partners from $386.00 to $360.00. They now have an “outperform” rating on the stock.
• 2/18/2026 – Insulet had its price target lowered by Canaccord Genuity Group Inc. from $450.00 to $435.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Insulet had its “buy” rating reaffirmed by BTIG Research. They now have a $380.00 price target on the stock.
• 2/4/2026 – Insulet had its price target lowered by Stifel Nicolaus from $370.00 to $350.00. They now have a “buy” rating on the stock.
• 1/26/2026 – Insulet was downgraded by TD Cowen from “buy” to “hold”. They now have a $294.00 price target on the stock.
• 1/22/2026 – Insulet had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 1/9/2026 – Insulet had its price target lowered by Sanford C. Bernstein from $410.00 to $380.00. They now have an “outperform” rating on the stock.
• 1/9/2026 – Insulet had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $365.00 price target on the stock.
• 1/5/2026 – Insulet was downgraded by Zacks Research from “strong-buy” to “hold”.

Insider Activity

In related news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.39% of the company’s stock.

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.